[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337467-105":59,"doc-detail-337467-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-the-nexus-of-nuclear-receptors-in-hematological-malignancies","Exploring the nexus of nuclear receptors in hematological malignancies","","Hematological malignancies (HM) are malignancies of the blood, bone marrow, and lymphatic systems, mainly including leukemia, lymphoma, and multiple myeloma. Outcomes vary and relapse risk remains high despite current therapies, especially in advanced disease where cures are lacking and drug resistance, recurrence, and severe side effects are common. Recent studies focus on nuclear receptors (NRs) for their control of tumor proliferation, differentiation, apoptosis evasion, invasion, and migration. Evidence supports targeting NR expression via agonists, antagonists, or selective modulators, and notes several FDA-approved anticancer agents, positioning NR-focused therapy as a promising route for more effective HM interventions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-nexus-of-nuclear-receptors-in-hematological-malignancies/337467/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-nexus-of-nuclear-receptors-in-hematological-malignancies/337467.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are hematological malignancies and which types are highlighted?","Question",{"text":112,"@type":113},"Hematological malignancies affect the blood, bone marrow, and lymphatic systems and are primarily categorized as leukemia, lymphoma, and multiple myeloma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is there a need for new therapeutic targets in hematological malignancies?",{"text":117,"@type":113},"Prognosis varies and relapse risk is frequent despite ongoing treatments, especially in advanced stages where cures are not available and drug resistance, recurrence, and severe side effects occur.",{"name":119,"@type":110,"acceptedAnswer":120},"How do nuclear receptors relate to tumor behavior in hematological malignancies?",{"text":121,"@type":113},"Nuclear receptors modulate tumor cell characteristics, including uncontrolled proliferation, differentiation, apoptosis evasion, invasion, and migration, making them clinically relevant targets.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337467,1790135036,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Cellular and Molecular Life Sciences (2024) 81:78  \n[https://doi.org/10.1007/s00018-023-05085-z](https://doi.org/10.1007/s00018-023-05085-z) Cellular and Molecular Life Sciences  \nExploring the nexus of nuclear receptors in hematological malignancies  \nMukesh Kumar Manickasamy1 · Anjana Sajeev1 · Bandari BharathwajChetty1 · Mohammed S. Alqahtani2,3 · Mohamed Abbas4 · Mangala Hegde1 · Babu Santha Aswani1 · Mehdi Shakibaei5 · Gautam Sethi6,7 · Ajaikumar B. Kunnumakkara1  \nReceived: 21 August 2023 / Revised: 16 November 2023 / Accepted: 3 December 2023 © The Author(s) 2024  \nAbstract  \nHematological malignancies (HM) represent a subset of neoplasms affecting the blood, bone marrow, and lymphatic systems, categorized primarily into leukemia, lymphoma, and multiple myeloma. Their prognosis varies considerably, with a frequent risk of relapse despite ongoing treatments. While contemporary therapeutic strategies have extended overall patient survival, they do not offer cures for advanced stages and often lead to challenges such as acquisition of drug resistance, recurrence, and severe side effects. The need for innovative therapeutic targets is vital to elevate both survival rates and patients' quality of life. Recent research has pivoted towards nuclear receptors (NRs) due to their role in modulating tumor cell characteristics including uncontrolled proliferation, differentiation, apoptosis evasion, invasion and migration. Existing evidence emphasizes NRs' critical role in HM. The regulation of NR expression through agonists, antagonists, or selective modulators, contingent upon their levels, offers promising clinical implications in HM management. Moreover, several anticancer agents targeting NRs have been approved by the Food and Drug Administration (FDA) . This review highlights the integral function of NRsin HM's pathophysiology and the potential benefits of therapeutically targeting these receptors, suggesting a prospective avenue for more efficient therapeutic interventions against HM.  \n* Gautam Sethi[phcgs@nus.edu.sg](phcgs@nus.edu.sg)  \n* Ajaikumar B. Kunnumakkara[kunnumakkara@iitg.ac.in](kunnumakkara@iitg.ac.in)  \nMukesh Kumar Manickasamy  \n[mm.kumar@iitg.ac.in](mm.kumar@iitg.ac.in)  \nAnjana Sajeev  \n[s.anjana@iitg.ac.in](s.anjana@iitg.ac.in)  \nBandari BharathwajChetty  \n[bharathwaj@iitg.ac.in](bharathwaj@iitg.ac.in)  \n[Mohammed S. Alqahtani](Mohammed S. Alqahtani)  \n[mosalqhtani@kku.edu.sa](mosalqhtani@kku.edu.sa)  \nMohamed Abbas  \n[mabas@kku.edu.sa](mabas@kku.edu.sa)  \nMangala Hegde  \n[mangala.hegde@rnd.iitg.ac.in](mangala.hegde@rnd.iitg.ac.in)  \nBabu Santha Aswani  \n[s.aswani@iitg.ac.in](s.aswani@iitg.ac.in)  \nMehdi Shakibaei  \n[mehdi.shakibaei@med.uni-muenchen.de](mehdi.shakibaei@med.uni-muenchen.de)  \n1 Cancer Biology Laboratory, Department of Biosciencesand Bioengineering, Indian Institute of Technology Guwahati (IITG), Guwahati, Assam 781039, India  \n2 Radiological Sciences Department, College of Applied Medical Sciences, King Khalid University, 61421 Abha, Saudi Arabia  \n3 BioImaging Unit, Space Research Centre, University of Leicester, Michael Atiyah Building, Leicester LE1 7RH, UK  \n4 Electrical Engineering Department, College of Engineering, King Khalid University, 61421 Abha, Saudi Arabia  \n5 Chair of Vegetative Anatomy, Department of Human-Anatomy, Musculoskeletal Research Group  \nand Tumor Biology, Institute of Anatomy, Ludwig-Maximilian-University, 80336 Munich, Germany  \n6 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore  \n7 NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore  \nGraphical abstract  \nKeywords Hematological malignancies · Leukemia · Lymphoma · Multiple myeloma · Nuclear receptors · Differentiation · Apoptosis · Homeostasis  \nAbbreviations  \nAA Amino acid  \nACTH Adrenocorticotropic hormone  \nAF 1 Activation function 1  \nAMPK AMP-activated pr","cbCaitMjhSCE3niT","https://ap.wps.com/l/cbCaitMjhSCE3niT","pdf",5049110,36,"English","# Abstract\n## Keywords\n## Abbreviations","[{\"question\":\"What are hematological malignancies and which types are highlighted?\",\"answer\":\"Hematological malignancies affect the blood, bone marrow, and lymphatic systems and are primarily categorized as leukemia, lymphoma, and multiple myeloma.\"},{\"question\":\"Why is there a need for new therapeutic targets in hematological malignancies?\",\"answer\":\"Prognosis varies and relapse risk is frequent despite ongoing treatments, especially in advanced stages where cures are not available and drug resistance, recurrence, and severe side effects occur.\"},{\"question\":\"How do nuclear receptors relate to tumor behavior in hematological malignancies?\",\"answer\":\"Nuclear receptors modulate tumor cell characteristics, including uncontrolled proliferation, differentiation, apoptosis evasion, invasion, and migration, making them clinically relevant targets.\"}]","Exploring the nexus of nuclear receptors in hematological malignancies | PDF",1790019243,91]